title: Degarelix as a new antiangiogenic agent for metastatic colon cancer?
abstract: Recently, follicle stimulating hormone receptor was found to be selectively expressed by endothelial cells on tumor-associated blood vessels in a wide range of human cancers. In this context, we hypothesized that degarelix, a new gonadotropin-releasing hormone receptor antagonist developed for patients with prostate cancer, may have antiangiogenic effects via its capacity to block follicle stimulating hormone (FSH) production. We report the case of a patient with metastatic colon cancer exhibiting tumor progression after failure of all conventional chemotherapeutic regimens. The addition of degarelix to the last chemotherapeutic regimen was proposed as compassionate treatment. Degarelix induced a rapid decrease in FSH level. This treatment induced radiological stabilization and carcinoembryonic antigen stabilization during 1 year. Contrast-enhanced ultrasonography demonstrated reduction of tumor vasculature. This case represents the first report of an antitumoral effect of degarelix in metastatic colon cancer and suggests an antiangiogenic property of this drug.
authors: Unite Mixte de Recherche 866, Institut National de la Sante et de la Recherche Medicale/Universite de Bourgogne, 21000 Dijon, France. fghiringhelli@cgfl.fr
authors: Francois
authors: F
authors: Ghiringhelli
authors: Nicolas
authors: N
authors: Isambert
authors: Sylvain
authors: S
authors: Ladoire
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D057176:Compassionate Use Trials; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D009389:Neovascularization, Pathologic; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D014463:Ultrasonography
chemical_list: D020533:Angiogenesis Inhibitors; D009842:Oligopeptides; C431566:acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
keywords: Angiogenesis; Antiangiogenic agents; Chemotherapy; Colon cancer; Degarelix